Multidrug Resistance (Mdr1) Gene Expression in Peripheral Blasts from Patients with Acute Leukemia Only Rarely Increases During Disease Progression after Combination Chemotherapy

References

• Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., Bennett J., Gottesman M., Pastan I. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br. J. Haematol. 1990; 75: 340–345
   PubMed Web of Science ®Google Scholar
• Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S.-I. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868–873
   PubMed Web of Science ®Google Scholar
• Pirker R., Wallner J., Geissler K., Linkesch W., Haas O.A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 1991; 83: 708–712
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Zhou D.-C., Marie J.-P., Suberville A.-M., Zittoun R. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879–885
   PubMed Web of Science ®Google Scholar
• TeBoekhorst P.A.W., De Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., Löwenberg B., Sonneveld P. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 82: 3157–3162
   PubMed Web of Science ®Google Scholar
• Goasguen J.E., Dossot J.-M., Fardel Le O., Mee F., LK Gall E., Leblay Le R., Prise P.Y., Chaperon J., Fawhet R. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–2398
   PubMed Web of Science ®Google Scholar
• Willman C.L., Kopecky K.J., Weick J., Appelbaum F., Grever M.R., Head D.R., Elias L., Balcerzak S.P., Mills G.M., Hynes H.E. Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased (complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside. Proc, ASCO. 1992; 11: 262
   Google Scholar
• Gruber A., Vitols S., Norgren S., Areström I., Peterson C., Björkholm M., Reizenstein P., Luthman H. Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br. J. Cancer 1992; 66: 266–272
   PubMed Web of Science ®Google Scholar
• Beck W.T., Danks M.K. Characteristics of multidrug resistance in human tumor cells. Molecular and cellular biology of multidrug resistance in rumor cells, I.B. Roninson. Plenum Press, New York 1991; 346
   Google Scholar
• Bhalla K., Huang Y., Tang C., Self S., Ray S., Mahoney M.E., Ponnathpur V., Tourkina E., Ibrado A.M., Bullock G., Willingham M.C. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 1994; 8: 465–475
   PubMed Web of Science ®Google Scholar
• Cassel A., Aghai E. Role of steroid hormones in the solution of multidrug resistance. Blood 1993; 82: 117a, suppl 1
   Google Scholar
• Lincke C.R., Van der Bliek A.M., Schuurhuis G.J., Van der Velde-Koerts T., Smit J.J.M., Borst P. Multidrug, resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 1990; 50: 1779–1785
   PubMed Web of Science ®Google Scholar
• Schurr E., Raymond M., Bell J.C., Gros P. Characterization of the multidrug resistance protein in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res 1989; 49: 2729–2734
   PubMed Web of Science ®Google Scholar
• Taylor C.W., Dalton W.S., Parrish P.R., Gleason M.C., Bellamy W.T., Thompson F.H., Roe D.J., Trent J.M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J. Cancer 1991; 63: 923–929
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Kawabata H., Nagumo N., Iida H., Kitatani Y., Tsukagoshi S., Sakurai Y. Potentiation of antitumor agets by calcium channel blockers with special reference to cross-resistance patterns. Cancer Chemother. Pharmacol. 1985; 15: 16–191
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Nooter K. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br. J. Haematol. 1990; 75: 208–211
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Durie B.G.M., Lokhorst H.M., Marie J.-P., Solbu G., Suciu S., Zittoun R., Löwenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporine. Lancet 1992; 340: 255–259
   PubMed Web of Science ®Google Scholar
• List A.F., Spier C., Greer J., Wolff S., Hutter J., Dorr R., Salmon S., Futscher B., Baier M., Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 1993; 11: 1652–1660
   PubMed Web of Science ®Google Scholar
• Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 1980; 102: 344–352
   PubMed Web of Science ®Google Scholar
• Ueda K., Clark D.P., Chen C., Roninson I.B., Gottesman M.M., Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 1987; 262: 505–508
   PubMed Web of Science ®Google Scholar
• Lowry U., Rownbrough N., Farr A., Randall K. Protein measurement with the Folk phenol reagent. J. Biol. Chem. 1951; 193: 265–775
   PubMed Web of Science ®Google Scholar
• Laemmili U.K. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 247–254
   Google Scholar
• Leith C.P., Kopecky K.J., Chen I.M., Griffith B.B., Appelbaum F.R., Willman C.L. Functional assessment of the multidrug (mdr1) resistance efflux pump in acute myeloid leukemia (AML): identification of CD34-, CD33+, MRK16+ Mdr1+) AML cases lacking functional dye efflux. Blood 1993; 82: 442a, Suppl 1
   Google Scholar
• Nygren P., Larsson R., Gruber A., Peterson C., Bergh J. Doxorubicin selected multidrug-re small cell lung cancer cell lines characterised by elevated zytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br. J. Cancer 1991; 64: 1011–1018
   PubMed Web of Science ®Google Scholar
• Barrand M.A., Rhodes T., Center M.S., Twentyman P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J. Cancer. 1993; 29A: 408–415
   PubMed Web of Science ®Google Scholar
• Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washingfon DC) 1992; 258: 1650–1654
   PubMed Web of Science ®Google Scholar
• Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J. Natl. Cancer Inst. 1990; 82: 1133–1140
   PubMed Web of Science ®Google Scholar
• Marie J.-P., Zittoun R., Sikic B.I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Musto P., Melillo L., Lombardi G., Matera Di R., Giorgio G., Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br. J. Haematol. 1991; 77: 50–53
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Geromin A., Michelutti A., Fanin R., Raspadon D., Russo D., Visani G., Dinota A., Pileri S., Tsuruo T., Grandi M., Baccarani M., Tura S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur. J. Haematol. 1992; 48: 87–92
   PubMed Web of Science ®Google Scholar
• Solary E., Bidan J.-M., Calvo F., Chauffert B., Caillot D., Mugneret F., Gauville C., Tsuruo T., Carli P.-M., Guy H. P-glycoprotein express ion and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia. 1991; 5: 592–597
   PubMed Web of Science ®Google Scholar
• Gekeler V., Frese G., Noller A., Handgretinger R., Wilisch A., Schmidt H., Muller C.P., Dopfer R., Klingehiel T., Diddens H., Probst H., Niethammer D. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase π gene expression in primary and relapsed state adult and childhood leukaemias. Br. J. Cancer 1992; 66: 507–517
   PubMed Web of Science ®Google Scholar
• Joncourt F., Oberli A., Redmond S.M.S., Fey M.E., Tobler A., Margison G.P., Gratwohl A., Buser K., Cerny T. Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, 06-alkylguanine-DNA-alkylytransferase and P-glycoprotein in adult patients with leukaemia. Br. J. Haematol. 1993; 85: 103–111
   PubMed Web of Science ®Google Scholar
• Ma D.D.F., Scurr R.D., Davey R.A., Mackertich S.M., Harman D.H., Dowden G., Isbister J.P., Bell D.R. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet. 1987; i: 135–137
   Google Scholar
• Ito Y., Tanimoto M., Kumazawa T., Okumura M., Morishima Y., Ohno R., Saito H. Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage. Cancer 1989; 63: 1534–1538
   PubMed Web of Science ®Google Scholar
• Goldstein L.I., Galski H., Fojo A., Willingham M., Lai S.-L., GadarPirker A.R., Green A., Crist W., Brodeur G.M., Lieber M., Cossman J., Gottesman M.M., Pastan I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 1989; 81: 116–124
   PubMed Web of Science ®Google Scholar
• Rothenberg M.L., Mickley L.A., Cole D.E., Balis F.M., Tsuruo T., Poplack D.G., Fojo A.T. Expression of the mdrl/P-170 gene in patients with acute lymphoblastic leukemia. Blood 1989; 74: 1388–1395
   PubMed Web of Science ®Google Scholar
• Albertioni F., Gruber A., Vitols S. Multidrug resistance gene (mdr1) RNA levels do not necessarily reflect P-glycoprotein content in acute leukemia cells. Proceedings of the 18th International Congress of Chemotherapy. 1993; 173, Stockholm 1993
   Google Scholar
• Hill B.T., Deuchars K., Hosking L.K., Ling V., Whelan R.D.H. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation. in vitro. J. Natl. Cancer. Inst. 1990; 82: 607–612
   PubMed Web of Science ®Google Scholar